Galapagos NV, the Belgian-based drug discovery group, said that income from partnerships as well as prospective orders for its service division, BioFocus DPI, should deliver revenues of €100 million in 2009 and a year-end cash balance of €20 million. In 2008, the company achieved revenue of €77 million, up by 17% from the previous year. Cash on 31 December was €27 million.
